|
EP1171468B1
(en)
*
|
1999-04-09 |
2008-07-02 |
Universität Zürich |
Method for the Stabilization of Chimeric Immunoglobulins or Immunoglobulin Fragments, and Stabilized Anti-EGP-2-scFv Fragment
|
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
US7754208B2
(en)
*
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7601351B1
(en)
|
2002-06-26 |
2009-10-13 |
Human Genome Sciences, Inc. |
Antibodies against protective antigen
|
|
PL2382990T3
(pl)
|
2003-04-30 |
2015-04-30 |
Univ Zuerich |
Sposoby leczenia raka z zastosowaniem immunotoksyny
|
|
CN1802388B
(zh)
|
2003-05-09 |
2011-01-05 |
杜克大学 |
Cd20特异抗体及使用它们的方法
|
|
ES2383300T3
(es)
|
2003-11-13 |
2012-06-20 |
Hanmi Holdings Co., Ltd |
Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
|
|
US8110665B2
(en)
|
2003-11-13 |
2012-02-07 |
Hanmi Holdings Co., Ltd. |
Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
|
|
AU2005334481A1
(en)
*
|
2004-08-11 |
2007-01-25 |
Trubion Pharmaceuticals, Inc. |
Binding domain fusion proteins
|
|
DK1810026T3
(en)
|
2004-10-06 |
2018-07-16 |
Mayo Found Medical Education & Res |
B7-H1 AND PD-1 FOR TREATMENT OF RENAL CELL CARCINOM
|
|
US8137907B2
(en)
|
2005-01-03 |
2012-03-20 |
Cold Spring Harbor Laboratory |
Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof
|
|
CN101160528A
(zh)
|
2005-02-14 |
2008-04-09 |
惠氏公司 |
Il17-f在诊断和治疗气道炎症中的用途
|
|
GT200600065A
(es)
*
|
2005-02-14 |
2006-10-02 |
|
Anticuerpos para interleucina-17f y otros antagonistas de la señalizacion de il-17f y sus usos
|
|
GT200600148A
(es)
*
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
|
JP2008540339A
(ja)
*
|
2005-04-29 |
2008-11-20 |
ワイス |
Ｎｏｇｏレセプター機能モチーフおよびそれに関するペプチド模倣物、ならびにそれらを使用する方法
|
|
US8188223B2
(en)
|
2005-05-18 |
2012-05-29 |
Ablynx N.V. |
Serum albumin binding proteins
|
|
CA2610265A1
(en)
|
2005-05-31 |
2007-05-10 |
Cold Spring Harbor Laboratory |
Methods for producing micrornas
|
|
WO2006133287A2
(en)
*
|
2005-06-06 |
2006-12-14 |
Wyeth |
Expression profiles of peripheral blood mononuclear cells for inflammatory bowel diseases
|
|
CA2611861C
(en)
|
2005-06-08 |
2017-11-28 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for the treatment of persistent infections
|
|
US20070014776A1
(en)
*
|
2005-06-09 |
2007-01-18 |
Gimeno Ruth E |
Identification of adiponutrin-related proteins as esterases and methods of use for the same
|
|
HUE029021T2
(en)
|
2005-06-21 |
2017-02-28 |
Xoma (Us) Llc |
IL-1beta-binding antibodies and fragments thereof
|
|
KR20080030656A
(ko)
*
|
2005-07-07 |
2008-04-04 |
콜레이 파마시티컬 그룹, 인코포레이티드 |
암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법
|
|
AU2006268111A1
(en)
*
|
2005-07-13 |
2007-01-18 |
Amgen Mountain View Inc. |
Il-6 binding proteins
|
|
RU2423381C2
(ru)
*
|
2005-07-25 |
2011-07-10 |
Трабьон Фармасьютикалз, Инк. |
Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
|
|
RU2421242C2
(ru)
|
2005-07-25 |
2011-06-20 |
Трабьон Фармасьютикалз, Инк. |
Применение однократной дозы cd20-специфических связывающих молекул
|
|
US20080279850A1
(en)
*
|
2005-07-25 |
2008-11-13 |
Trubion Pharmaceuticals, Inc. |
B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
|
|
PL2407486T3
(pl)
*
|
2005-08-19 |
2018-05-30 |
Wyeth Llc |
Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
|
|
EP1945240B1
(en)
|
2005-09-16 |
2016-12-28 |
Raptor Pharmaceutical Inc |
Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
|
|
CA2631184A1
(en)
*
|
2005-11-28 |
2007-05-31 |
Genmab A/S |
Recombinant monovalent antibodies and methods for production thereof
|
|
TW200744634A
(en)
|
2006-02-21 |
2007-12-16 |
Wyeth Corp |
Methods of using antibodies against human IL-22
|
|
TWI417301B
(zh)
|
2006-02-21 |
2013-12-01 |
Wyeth Corp |
對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
|
|
JP2009529915A
(ja)
|
2006-03-20 |
2009-08-27 |
ゾーマ テクノロジー リミテッド |
ガストリン物質に対して特異的なヒト抗体および方法
|
|
WO2007109749A2
(en)
*
|
2006-03-21 |
2007-09-27 |
Wyeth |
Methods for preventing and treating amyloidogenic diseases
|
|
AU2007238034A1
(en)
*
|
2006-04-14 |
2007-10-25 |
Trubion Pharmaceuticals Inc. |
Binding proteins comprising immunoglobulin hinge and Fc regions having altered Fc effector functions
|
|
JP2009534040A
(ja)
*
|
2006-04-19 |
2009-09-24 |
ワイス |
Ｉｒｅｓ配列を標的とする短鎖干渉ｒｎａ二本鎖及びそのための使用
|
|
JP2009534035A
(ja)
*
|
2006-04-21 |
2009-09-24 |
ワイス |
細胞系のハイスループットスクリーニング方法
|
|
ES2469676T3
(es)
*
|
2006-05-25 |
2014-06-18 |
Bayer Intellectual Property Gmbh |
Complejos moleculares dim�ricos
|
|
JP2009538140A
(ja)
*
|
2006-05-25 |
2009-11-05 |
ワイス |
血管疾患および炎症性疾患でのシステインプロテアーゼレグマインの発現
|
|
AU2016231617B2
(en)
*
|
2006-06-12 |
2018-08-23 |
Aptevo Research And Development Llc |
Single-chain multivalent binding proteins with effector function
|
|
NZ573646A
(en)
*
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
|
US20080027001A1
(en)
*
|
2006-07-07 |
2008-01-31 |
Andrew Wood |
Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
|
|
WO2008011571A1
(en)
*
|
2006-07-21 |
2008-01-24 |
Amgen Inc. |
Polypeptides with reduced susceptibility to oxidation and methods of making
|
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
CA2659820A1
(en)
*
|
2006-08-04 |
2008-02-14 |
Novartis Ag |
Ephb3-specific antibody and uses thereof
|
|
AR064801A1
(es)
|
2006-08-18 |
2009-04-29 |
Xoma Technology Ltd |
Anticuerpo especifico prlr (receptor de prolactina) y sus usos
|
|
AU2007286754A1
(en)
*
|
2006-08-25 |
2008-02-28 |
Viropharma Incorporated |
Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
|
|
CN101511387A
(zh)
*
|
2006-09-08 |
2009-08-19 |
惠氏公司 |
使用亲和色谱法纯化蛋白质的精氨酸洗涤液
|
|
RU2495882C2
(ru)
|
2006-09-08 |
2013-10-20 |
Медиммун, Ллк. |
Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания
|
|
US20080132688A1
(en)
*
|
2006-09-22 |
2008-06-05 |
Amgen Inc. |
Methods for Removing Viral Contaminants During Protein Purification
|
|
EP2076287A2
(en)
*
|
2006-10-12 |
2009-07-08 |
Wyeth |
Methods and compositions with reduced opalescence
|
|
US7846434B2
(en)
*
|
2006-10-24 |
2010-12-07 |
Trubion Pharmaceuticals, Inc. |
Materials and methods for improved immunoglycoproteins
|
|
JP2010507394A
(ja)
*
|
2006-10-24 |
2010-03-11 |
トルービオン ファーマスーティカルズ インコーポレイテッド |
改良免疫糖タンパク質のための物質および方法
|
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
|
CA2673331A1
(en)
|
2006-12-19 |
2008-06-26 |
Ablynx N.V. |
Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
|
|
EP2102244A2
(en)
|
2006-12-19 |
2009-09-23 |
Ablynx N.V. |
Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
|
|
EP3124045A3
(en)
|
2006-12-20 |
2017-05-03 |
Xoma (Us) Llc |
Treatment of il-1 beta related diseases
|
|
KR101523391B1
(ko)
*
|
2006-12-27 |
2015-05-27 |
에모리 유니버시티 |
감염 및 종양 치료를 위한 조성물 및 방법
|
|
TW201307390A
(zh)
*
|
2007-02-02 |
2013-02-16 |
Amgen Inc |
海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
|
|
WO2008104803A2
(en)
|
2007-02-26 |
2008-09-04 |
Oxford Genome Sciences (Uk) Limited |
Proteins
|
|
TW200902064A
(en)
*
|
2007-03-28 |
2009-01-16 |
Wyeth Corp |
Methods and compositions for modulating IL-17F/IL-17A biological activity
|
|
TW200902708A
(en)
*
|
2007-04-23 |
2009-01-16 |
Wyeth Corp |
Methods of protein production using anti-senescence compounds
|
|
WO2008142028A1
(en)
|
2007-05-17 |
2008-11-27 |
Boehringer Ingelheim Rcv Gmbh & Co Kg |
Method for producing a recombinant protein on a manufacturing scale
|
|
US20090304590A1
(en)
*
|
2007-05-29 |
2009-12-10 |
Wyeth |
Therapeutic compositions and methods
|
|
US20090258005A1
(en)
*
|
2007-05-29 |
2009-10-15 |
Trubion Pharmaceuticals Inc. |
Therapeutic compositions and methods
|
|
ES2623925T3
(es)
*
|
2007-05-30 |
2017-07-12 |
Postech Academy-Industry- Foundation |
Proteínas de fusión de inmunoglobulina
|
|
JP5511654B2
(ja)
*
|
2007-05-31 |
2014-06-04 |
ゲンマブ エー／エス |
分子操作により得られた組換え非グリコシル化一価半抗体
|
|
ES2657055T3
(es)
|
2007-08-09 |
2018-03-01 |
Wyeth Llc |
Uso de perfusión para mejorar la producción de un cultivo de células alimentado por lotes en biorreactores
|
|
PE20140196A1
(es)
|
2007-08-09 |
2014-03-19 |
Boehringer Ingelheim Int |
Anticuerpos anti-cd37
|
|
US20090304719A1
(en)
|
2007-08-22 |
2009-12-10 |
Patrick Daugherty |
Activatable binding polypeptides and methods of identification and use thereof
|
|
JP5607530B2
(ja)
|
2007-09-04 |
2014-10-15 |
コンピュゲン エルティーディー． |
ポリペプチド並びにポリヌクレオチド、並びに薬剤および生物製剤生産のための薬剤標的としてのその利用
|
|
EP2205280B1
(en)
*
|
2007-09-27 |
2019-09-04 |
Amgen Inc. |
Pharmaceutical formulations
|
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
|
EP2612867A1
(en)
*
|
2007-11-01 |
2013-07-10 |
Perseid Therapeutics LLC |
Immunosuppressive polypeptides and nucleic acids
|
|
AU2014250683B2
(en)
*
|
2007-11-01 |
2015-11-26 |
Astellas Pharma Inc. |
Immunosuppressive polypeptides and nucleic acids
|
|
US8796206B2
(en)
|
2007-11-15 |
2014-08-05 |
Amgen Inc. |
Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
|
|
SI2391650T1
(sl)
|
2007-12-20 |
2015-03-31 |
Xoma (Us) Llc |
Postopki za zdravljenje protina
|
|
WO2009086072A2
(en)
|
2007-12-21 |
2009-07-09 |
Genentech, Inc. |
Therapy of rituximab-refractory rheumatoid arthritis patients
|
|
EP2235058A2
(en)
|
2007-12-21 |
2010-10-06 |
Amgen, Inc |
Anti-amyloid antibodies and uses thereof
|
|
WO2009094551A1
(en)
|
2008-01-25 |
2009-07-30 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
|
CN101977932B
(zh)
*
|
2008-01-31 |
2014-09-03 |
美国政府健康及人类服务部 |
工程化抗体恒定结构域分子
|
|
AU2014200215B2
(en)
*
|
2008-01-31 |
2016-09-29 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Engineered antibody constant domain molecules
|
|
CA2716801A1
(en)
*
|
2008-03-12 |
2009-09-17 |
Wyeth Llc |
Methods for identifying cells suitable for large-scale production of recombinant proteins
|
|
JP2011516520A
(ja)
|
2008-04-07 |
2011-05-26 |
アブリンクス エン．ヴェー． |
Ｎｏｔｃｈ経路に指向性を有するアミノ酸配列及びその使用
|
|
RU2531754C2
(ru)
|
2008-04-11 |
2014-10-27 |
ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US |
Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
|
|
US20090269339A1
(en)
*
|
2008-04-29 |
2009-10-29 |
Genentech, Inc. |
Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
|
|
US9315577B2
(en)
|
2008-05-01 |
2016-04-19 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
|
CA2732574A1
(en)
*
|
2008-07-28 |
2010-02-04 |
Philip Tan |
Multi-specific binding proteins targeting b cell disorders
|
|
AU2009286956B2
(en)
|
2008-08-28 |
2012-12-06 |
Novartis Ag |
Cell surface display of polypeptide isoforms by stop codon readthrough
|
|
AR073295A1
(es)
|
2008-09-16 |
2010-10-28 |
Genentech Inc |
Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
|
|
US20100075329A1
(en)
|
2008-09-23 |
2010-03-25 |
O'toole Margot |
Methods for predicting production of activating signals by cross-linked binding proteins
|
|
US20100113304A1
(en)
*
|
2008-09-26 |
2010-05-06 |
Wyeth |
Compatible display vector systems
|
|
JP2012503982A
(ja)
|
2008-09-26 |
2012-02-16 |
ワイス・エルエルシー |
適合性ディスプレイベクター系
|
|
NO2344540T3
(https=)
|
2008-10-02 |
2018-04-28 |
|
|
|
AU2009303318B2
(en)
*
|
2008-10-10 |
2016-06-30 |
Aptevo Research And Development Llc |
TCR complex immunotherapeutics
|
|
JP2012507565A
(ja)
|
2008-10-30 |
2012-03-29 |
グオ・ペイシュエン |
Ｄｎａのシークエンシング及び他の用途のための、膜に組み込まれたウイルスｄｎａパッケージングモータタンパク質コネクタバイオセンサ
|
|
WO2010057047A1
(en)
*
|
2008-11-13 |
2010-05-20 |
Trubion Pharmaceutics, Inc. |
Cd37 immunotherapeutic combination therapies and uses thereof
|
|
KR20110097772A
(ko)
*
|
2008-11-17 |
2011-08-31 |
제넨테크, 인크. |
생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제
|
|
MX2011005691A
(es)
*
|
2008-11-28 |
2011-07-20 |
Univ Emory |
Metodos para el tratamiento de infecciones y tumores.
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
RU2636046C2
(ru)
|
2009-01-12 |
2017-11-17 |
Сайтомкс Терапьютикс, Инк |
Композиции модифицированных антител, способы их получения и применения
|
|
AU2010215761B2
(en)
|
2009-02-23 |
2017-04-06 |
Cytomx Therapeutics, Inc |
Proproteins and methods of use thereof
|
|
WO2010147686A2
(en)
|
2009-03-11 |
2010-12-23 |
Wyeth Llc |
Methods of purifying small modular immunopharmaceutical proteins
|
|
JP2010213694A
(ja)
|
2009-03-12 |
2010-09-30 |
Wyeth Llc |
ＰＫＮ３／ＲｈｏＣ高分子複合体およびその使用方法
|
|
CA2755336C
(en)
|
2009-03-20 |
2015-07-14 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
|
EP2411125B1
(en)
|
2009-03-24 |
2019-05-08 |
Wyeth LLC |
Membrane evaporation for generating highly concentrated protein therapeutics
|
|
NZ595461A
(en)
|
2009-04-10 |
2013-01-25 |
Ablynx Nv |
Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
|
|
WO2010132697A2
(en)
*
|
2009-05-13 |
2010-11-18 |
Genzyme Corporation |
Methods and compositions for treatment
|
|
PT2438087T
(pt)
|
2009-06-05 |
2017-08-04 |
Ablynx Nv |
Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório
|
|
EP2451487A1
(en)
|
2009-07-09 |
2012-05-16 |
F. Hoffmann-La Roche AG |
In vivi tumor vasculature imaging
|
|
WO2011030107A1
(en)
|
2009-09-10 |
2011-03-17 |
Ucb Pharma S.A. |
Multivalent antibodies
|
|
EP2480888B1
(en)
|
2009-09-25 |
2016-11-30 |
XOMA Technology Ltd. |
Screening methods
|
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
|
MX341084B
(es)
|
2009-11-02 |
2016-08-05 |
Univ Washington |
Composiciones de nucleasas terapéuticas y métodos.
|
|
US20120231006A1
(en)
|
2009-11-20 |
2012-09-13 |
Amgen Inc. |
Anti-orai1 antigen binding proteins and uses thereof
|
|
DE102009047243A1
(de)
*
|
2009-11-27 |
2011-06-01 |
Orgentec Diagnostika Gmbh |
Monospezifische Polypeptidreagenzien
|
|
WO2011064382A1
(en)
|
2009-11-30 |
2011-06-03 |
Ablynx N.V. |
Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
|
|
EP3309176B1
(en)
|
2009-12-14 |
2025-10-01 |
Ablynx N.V. |
Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
|
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
|
WO2011079308A2
(en)
|
2009-12-23 |
2011-06-30 |
Emergent Product Development Seattle, Llc |
Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
|
|
CA2785907A1
(en)
|
2009-12-29 |
2011-07-28 |
Emergent Product Development Seattle, Llc |
Ron binding constructs and methods of use thereof
|
|
WO2011083140A1
(en)
|
2010-01-08 |
2011-07-14 |
Ablynx Nv |
Immunoglobulin single variable domain directed against human cxcr4
|
|
US9120855B2
(en)
|
2010-02-10 |
2015-09-01 |
Novartis Ag |
Biologic compounds directed against death receptor 5
|
|
KR20130009760A
(ko)
|
2010-02-10 |
2013-01-23 |
이뮤노젠 아이엔씨 |
Ｃｄ２０ 항체 및 이의 용도
|
|
US9260529B2
(en)
|
2010-02-24 |
2016-02-16 |
The University Of Washington Through Its Center For Commercialization |
Molecules that bind CD180, compositions and methods of use
|
|
SG10201501803YA
(en)
*
|
2010-03-12 |
2015-05-28 |
Immunogen Inc |
Cd37-binding molecules and immunoconjugates thereof
|
|
CA2793778A1
(en)
|
2010-04-05 |
2011-11-13 |
Wyeth Llc |
Biomarkers for p13k-driven cancer
|
|
SMT202000095T1
(it)
|
2010-05-14 |
2020-03-13 |
Amgen Inc |
Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
|
|
EP2571901B1
(en)
|
2010-05-20 |
2019-01-02 |
Ablynx N.V. |
Biological materials related to her3
|
|
US9428546B2
(en)
|
2010-07-30 |
2016-08-30 |
Pfizer Inc. |
Tandem purification of proteins
|
|
KR20130045914A
(ko)
|
2010-08-03 |
2013-05-06 |
에프. 호프만-라 로슈 아게 |
만성 림프구성 백혈병(cll) 생체지표
|
|
AU2011289426A1
(en)
|
2010-08-10 |
2013-02-28 |
Amgen Inc. |
Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
|
|
CA2809089C
(en)
|
2010-08-23 |
2018-12-18 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
MX360946B
(es)
|
2010-09-22 |
2018-10-29 |
Amgen Inc Star |
Inmunoglobulinas portadoras y usos de las mismas.
|
|
AU2011328246B2
(en)
|
2010-11-08 |
2016-06-30 |
Ablynx N.V. |
CXCR2 binding polypeptides
|
|
WO2012064733A2
(en)
*
|
2010-11-09 |
2012-05-18 |
Medimmune, Llc |
Antibody scaffold for homogenous conjugation
|
|
CA2818173C
(en)
|
2010-11-30 |
2022-05-03 |
Genentech, Inc. |
Low affinity blood brain barrier receptor antibodies and uses therefor
|
|
ES2617983T3
(es)
|
2011-01-10 |
2017-06-20 |
Ct Atlantic Ltd. |
Terapia de combinación que incluye anticuerpos de unión a antígenos asociados a tumores
|
|
EP2673297A2
(en)
|
2011-02-11 |
2013-12-18 |
Zyngenia, Inc. |
Monovalent and multivalent multispecific complexes and uses thereof
|
|
EP2686418A4
(en)
|
2011-03-17 |
2015-04-22 |
Minerva Biotechnologies Corp |
METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
|
|
AU2012236210B2
(en)
|
2011-04-01 |
2016-02-04 |
Immunogen, Inc. |
CD37-binding molecules and immunoconjugates thereof
|
|
EP3415528B1
(en)
*
|
2011-04-13 |
2021-05-26 |
Bristol-Myers Squibb Company |
Fc fusion proteins comprising novel linkers or arrangements
|
|
EP2699596A4
(en)
*
|
2011-04-22 |
2015-01-14 |
Emergent Product Dev Seattle |
PROSTATE-SPECIFIC MEMBRANE-BINDING PROTEINS AND COMPOSITIONS AND METHOD THEREFOR
|
|
ES2666303T3
(es)
|
2011-04-29 |
2018-05-03 |
University Of Washington |
Composiciones terapéuticas de nucleasa y métodos
|
|
UA117218C2
(uk)
|
2011-05-05 |
2018-07-10 |
Мерк Патент Гмбх |
Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
|
|
WO2012154759A2
(en)
*
|
2011-05-09 |
2012-11-15 |
Minerva Biotechnologies Corporation |
Genetically engineered growth factor variants
|
|
JP2014524891A
(ja)
|
2011-06-03 |
2014-09-25 |
シーティー アトランティック リミテッド |
Ｍａｇｅａ３結合抗体
|
|
WO2012163771A1
(en)
|
2011-06-03 |
2012-12-06 |
Ct Atlantic Ltd. |
Magea3 binding antibodies
|
|
CN103732623B
(zh)
|
2011-06-03 |
2017-09-29 |
佐马技术有限公司 |
对TGF‑β具有特异性的抗体
|
|
CN102836441B
(zh)
*
|
2011-06-24 |
2019-06-11 |
台北荣民总医院 |
于感染性与恶性疾病的治疗中提升免疫反应的方法
|
|
CN103796681B
(zh)
|
2011-06-30 |
2018-07-20 |
建新公司 |
T细胞活化的抑制剂
|
|
US9428574B2
(en)
|
2011-06-30 |
2016-08-30 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
|
EP2734232B1
(en)
|
2011-07-19 |
2017-11-01 |
Philogen S.p.A. |
Sequential anti-ctla4 and targeted il-2 therapy
|
|
UY34317A
(es)
|
2011-09-12 |
2013-02-28 |
Genzyme Corp |
Anticuerpo antireceptor de célula T (alfa)/ß
|
|
WO2013096516A1
(en)
|
2011-12-19 |
2013-06-27 |
Xoma Technology Ltd. |
Methods for treating acne
|
|
CA2848985A1
(en)
|
2012-02-01 |
2013-08-08 |
Compugen Ltd. |
C10rf32 antibodies, and uses thereof for treatment of cancer
|
|
WO2013156054A1
(en)
*
|
2012-04-16 |
2013-10-24 |
Universität Stuttgart |
The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
|
|
JP6509724B2
(ja)
|
2012-04-20 |
2019-05-08 |
アプティーボ リサーチ アンド デベロップメント エルエルシー |
Ｃｄ３結合ポリペプチド
|
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
|
JP2015517511A
(ja)
|
2012-05-16 |
2015-06-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
|
|
KR101704893B1
(ko)
|
2012-06-15 |
2017-02-08 |
화이자 인코포레이티드 |
Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
|
|
JP5600758B2
(ja)
*
|
2013-01-23 |
2014-10-01 |
バイエル・ファルマ・アクチェンゲゼルシャフト |
二量体分子複合体
|
|
CA2919076C
(en)
*
|
2013-07-31 |
2024-01-30 |
Amgen Inc. |
Stabilization of fc-containing polypeptides
|
|
WO2015035342A2
(en)
|
2013-09-08 |
2015-03-12 |
Oligasis Llc |
Factor viii zwitterionic polymer conjugates
|
|
WO2015048901A1
(en)
|
2013-10-02 |
2015-04-09 |
Viventia Bio Inc. |
Anti-epcam antibodies and methods of use
|
|
CN105745224B
(zh)
|
2013-10-11 |
2019-11-05 |
牛津生物疗法有限公司 |
用于治疗癌症的针对ly75的偶联抗体
|
|
HRP20192080T1
(hr)
|
2013-10-31 |
2020-02-07 |
Resolve Therapeutics, Llc |
Terapeutske fuzije nukleaza-albumine i postupci
|
|
WO2015070210A1
(en)
|
2013-11-11 |
2015-05-14 |
Wake Forest University Health Sciences |
Epha3 and multi-valent targeting of tumors
|
|
EP3077823B1
(en)
|
2013-12-05 |
2019-09-04 |
The Broad Institute, Inc. |
Compositions and methods for identifying and treating cachexia or pre-cachexia
|
|
PE20170255A1
(es)
|
2014-01-24 |
2017-03-22 |
Dana Farber Cancer Inst Inc |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
|
|
CN112851769A
(zh)
|
2014-01-27 |
2021-05-28 |
分子模板公司 |
用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
|
|
HUE045065T2
(hu)
|
2014-01-31 |
2019-12-30 |
Novartis Ag |
TIM-3 antitest molekulák és felhasználásaik
|
|
US11142584B2
(en)
*
|
2014-03-11 |
2021-10-12 |
Molecular Templates, Inc. |
CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
|
|
KR102442436B1
(ko)
|
2014-03-14 |
2022-09-15 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
|
US20170335281A1
(en)
|
2014-03-15 |
2017-11-23 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
|
PT3122769T
(pt)
*
|
2014-03-28 |
2023-04-24 |
Univ Minnesota |
Polipéptidos, células e métodos que envolvem cd16 manipulado
|
|
PL3560954T3
(pl)
|
2014-04-03 |
2021-12-13 |
Igm Biosciences, Inc. |
Zmodyfikowany łańcuch J
|
|
EP4707303A2
(en)
|
2014-05-16 |
2026-03-11 |
Ablynx NV |
Improved immunoglobulin variable domains
|
|
IL318433A
(en)
|
2014-05-16 |
2025-03-01 |
Ablynx Nv |
Improved immunoglobulin variable complexes
|
|
NL2013661B1
(en)
|
2014-10-21 |
2016-10-05 |
Ablynx Nv |
KV1.3 Binding immunoglobulins.
|
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
BR112017001183A2
(pt)
|
2014-07-21 |
2017-11-28 |
Novartis Ag |
tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
|
|
TWI719942B
(zh)
|
2014-07-21 |
2021-03-01 |
瑞士商諾華公司 |
使用ｃｄ３３嵌合抗原受體治療癌症
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
EP2985294A1
(en)
*
|
2014-08-14 |
2016-02-17 |
Deutsches Krebsforschungszentrum |
Recombinant antibody molecule and its use for target cell restricted T cell activation
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
MX2017002205A
(es)
|
2014-08-19 |
2017-08-21 |
Novartis Ag |
Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
|
|
WO2016044224A1
(en)
|
2014-09-15 |
2016-03-24 |
Amgen Inc. |
Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
KR20210013299A
(ko)
|
2014-10-17 |
2021-02-03 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
|
EP3221351B1
(en)
*
|
2014-11-19 |
2024-11-13 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for cancer treating conditions relating to over expressions of epha2
|
|
EP3026060A1
(en)
*
|
2014-11-26 |
2016-06-01 |
Miltenyi Biotec GmbH |
Humanized antibody or fragment thereof specific for CD45R0
|
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
|
JP6849600B6
(ja)
|
2015-01-29 |
2021-06-30 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
キメラ抗原受容体、組成物及び方法
|
|
EP3253799B1
(en)
*
|
2015-02-05 |
2020-12-02 |
Molecular Templates, Inc. |
Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
|
|
US10711067B2
(en)
|
2015-03-03 |
2020-07-14 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
|
EP3957738A1
(en)
|
2015-03-04 |
2022-02-23 |
IGM Biosciences, Inc. |
Cd20 binding molecules and uses thereof
|
|
CA2979394A1
(en)
|
2015-03-12 |
2016-09-15 |
Viventia Bio Inc. |
Methods of treatment for epcam positive bladder cancer
|
|
CN107580501A
(zh)
|
2015-03-12 |
2018-01-12 |
维文蒂亚生物公司 |
用于靶向epcam阳性膀胱癌的给药策略
|
|
EP3770171A1
(en)
|
2015-04-03 |
2021-01-27 |
XOMA Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
|
RS61907B1
(sr)
|
2015-04-06 |
2021-06-30 |
Subdomain Llc |
Polipeptidi koji sadrže de novo vezujući domen i njihova primena
|
|
JP6961490B2
(ja)
|
2015-04-08 |
2021-11-05 |
ノバルティス アーゲー |
Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
|
|
GB201506402D0
(en)
*
|
2015-04-15 |
2015-05-27 |
Berkel Patricius H C Van And Howard Philip W |
Site-specific antibody-drug conjugates
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
SG11201708804WA
(en)
|
2015-05-07 |
2017-11-29 |
Agenus Inc |
Anti-ox40 antibodies and methods of use thereof
|
|
EP3154439A1
(en)
|
2015-05-19 |
2017-04-19 |
Yaya Diagnostics GmbH |
Means and methods for the enrichment of nucleic acids
|
|
EP3303373B1
(en)
|
2015-05-30 |
2020-04-08 |
Molecular Templates, Inc. |
De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
|
|
EP3303392B1
(en)
|
2015-06-01 |
2020-08-05 |
Medigene Immunotherapies GmbH |
Method for generating antibodies against t cell receptor
|
|
JP2018517712A
(ja)
|
2015-06-01 |
2018-07-05 |
メディジーン イミュノテラピーズ ゲーエムベーハー |
Ｔ細胞受容体特異的抗体
|
|
EA201792660A1
(ru)
|
2015-06-01 |
2018-05-31 |
Медиджин Иммьюнотерапиз Гмбх |
Библиотека т-клеточных рецепторов
|
|
EP3302561A4
(en)
|
2015-06-08 |
2019-02-06 |
Debiopharm International SA |
COMBINATIONS OF ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODIES
|
|
HRP20211058T8
(hr)
|
2015-07-29 |
2021-11-26 |
Novartis Ag |
Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
CA2994841A1
(en)
|
2015-08-06 |
2017-02-09 |
Xoma (Us) Llc |
Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
|
|
WO2017021023A1
(en)
|
2015-08-06 |
2017-02-09 |
Yaya Diagnostics Gmbh |
Means and methods for the detection of targets
|
|
KR102766022B1
(ko)
|
2015-08-28 |
2025-02-10 |
데비오팜 인터네셔날 에스 에이 |
Cd37 의 검출을 위한 항체 및 검정
|
|
WO2017053469A2
(en)
|
2015-09-21 |
2017-03-30 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
|
EP3356401B1
(en)
|
2015-09-30 |
2020-06-24 |
IGM Biosciences, Inc. |
Binding molecules with modified j-chain
|
|
EP3355913B1
(en)
|
2015-09-30 |
2024-10-30 |
IGM Biosciences, Inc. |
Binding molecules with modified j-chain
|
|
CN108883173B
(zh)
|
2015-12-02 |
2022-09-06 |
阿吉纳斯公司 |
抗体和其使用方法
|
|
WO2017106196A1
(en)
|
2015-12-14 |
2017-06-22 |
The Broad Institute, Inc. |
Compositions and methods for treating cardiac dysfunction
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
US20200261573A1
(en)
|
2015-12-17 |
2020-08-20 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
|
EP4643874A3
(en)
|
2015-12-22 |
2026-02-11 |
Novartis AG |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
|
TWI752930B
(zh)
|
2015-12-23 |
2022-01-21 |
德商梅迪基因免疫治療公司 |
抗原特異性ｔｃｒ的新生成
|
|
KR20250057128A
(ko)
|
2015-12-30 |
2025-04-28 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
MA55746A
(fr)
|
2016-01-21 |
2022-03-02 |
Novartis Ag |
Molécules multispécifiques ciblant cll-1
|
|
KR20180118175A
(ko)
|
2016-03-04 |
2018-10-30 |
노파르티스 아게 |
다중 키메라 항원 수용체 (car) 분자를 발현하는 세포 및 그에 따른 용도
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
KR102486507B1
(ko)
|
2016-04-08 |
2023-01-09 |
아이티아이 헬스, 인크. |
플렉틴-1 결합 항체 및 그의 용도
|
|
CN109715808A
(zh)
|
2016-04-15 |
2019-05-03 |
诺华股份有限公司 |
用于选择性蛋白质表达的组合物和方法
|
|
KR102682118B1
(ko)
|
2016-04-29 |
2024-07-08 |
주식회사유한양행 |
Ccl3 변이체를 포함하는 융합 단백질 및 이의 용도
|
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
CA3029627A1
(en)
|
2016-07-01 |
2018-01-04 |
Resolve Therapeutics, Llc |
Optimized binuclease fusions and methods
|
|
SG11201900344YA
(en)
|
2016-07-15 |
2019-02-27 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
AU2017302668B9
(en)
|
2016-07-28 |
2023-06-22 |
Novartis Ag |
Combination therapies of chimeric antigen receptors and PD-1 inhibitors
|
|
BR112019002035A2
(pt)
|
2016-08-01 |
2019-05-14 |
Novartis Ag |
tratamento de câncer usando um receptor de antígeno quimérico em combinação com um inibidor de uma molécula pró-macrófago m2
|
|
CN109803680B
(zh)
|
2016-08-01 |
2024-05-17 |
佐马美国有限公司 |
甲状旁腺激素受体1(pth1r)抗体和其用途
|
|
US11259739B2
(en)
*
|
2016-08-12 |
2022-03-01 |
Phd Preventative Health Care And Diagnostics, Inc. |
Immunotherapy treatment kit and method of using the same
|
|
AU2017335771A1
(en)
|
2016-09-28 |
2019-02-28 |
Musc Foundation For Research Development |
Antibodies that bind interleukin-2 and uses thereof
|
|
BR112019006781A2
(pt)
|
2016-10-07 |
2019-07-30 |
Novartis Ag |
receptores de antígeno quiméricos para o tratamento de câncer
|
|
AU2017332960B2
(en)
|
2016-10-20 |
2019-09-12 |
I-Mab Biopharma Us Limited |
Novel CD47 monoclonal antibodies and uses thereof
|
|
EP3535297B1
(en)
|
2016-11-02 |
2022-08-10 |
Debiopharm International, S.A. |
Methods for improving anti-cd37 immunoconjugate therapy
|
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
|
MX2019005552A
(es)
|
2016-11-14 |
2019-08-12 |
Amgen Inc |
Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.
|
|
BR112019010061A2
(pt)
|
2016-11-16 |
2019-08-13 |
Ablynx Nv |
polipeptídeos de recrutamento de células t capazes de se ligarem ao cd123 e tcr alfa/beta
|
|
WO2018106895A1
(en)
|
2016-12-07 |
2018-06-14 |
Molecular Templates, Inc. |
Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
|
|
BR112019012328A2
(pt)
|
2016-12-15 |
2019-11-19 |
Abbvie Biotherapeutics Inc |
anticorpos anti-ox40 e seus usos
|
|
ES2973548T3
(es)
|
2016-12-22 |
2024-06-20 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
|
|
WO2018120842A1
(zh)
*
|
2016-12-30 |
2018-07-05 |
上海欣百诺生物科技有限公司 |
一种双功能分子及其应用
|
|
MX2019008840A
(es)
|
2017-01-25 |
2019-09-09 |
Molecular Templates Inc |
Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
|
|
ES2912408T3
(es)
|
2017-01-26 |
2022-05-25 |
Novartis Ag |
Composiciones de CD28 y métodos para terapia con receptores quiméricos para antígenos
|
|
WO2018160731A1
(en)
|
2017-02-28 |
2018-09-07 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
JP7330942B2
(ja)
*
|
2017-03-31 |
2023-08-22 |
ジェンマブ ホールディング ビー．ブイ． |
二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
MY204117A
(en)
|
2017-06-22 |
2024-08-08 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
CA3066747A1
(en)
|
2017-06-27 |
2019-01-03 |
Novartis Ag |
Dosage regimens for anti-tim-3 antibodies and uses thereof
|
|
AU2018301393B2
(en)
|
2017-07-11 |
2025-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
|
JP2020527572A
(ja)
|
2017-07-20 |
2020-09-10 |
ノバルティス アーゲー |
抗ｌａｇ−３抗体の投薬量レジメンおよびその使用
|
|
CA3073537A1
(en)
|
2017-08-22 |
2019-02-28 |
Sanabio, Llc |
Soluble interferon receptors and uses thereof
|
|
JP7379347B2
(ja)
*
|
2017-10-11 |
2023-11-14 |
ジィールバイオ，インコーポレーテッド |
プレクチン１結合抗体およびその使用
|
|
US20200283501A1
(en)
|
2017-10-26 |
2020-09-10 |
Regents Of The University Of Minnesota |
Recombinant immune cells, methods of making, and methods of use
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
RS67119B1
(sr)
|
2017-11-14 |
2025-09-30 |
Arcellx Inc |
Polipeptidi koji obuhvataju d domen i njihove upotrebe
|
|
CN111655288A
(zh)
|
2017-11-16 |
2020-09-11 |
诺华股份有限公司 |
组合疗法
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
CN109957017A
(zh)
*
|
2017-12-25 |
2019-07-02 |
深圳宾德生物技术有限公司 |
一种靶向ox40的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
|
|
CN109957022A
(zh)
*
|
2017-12-25 |
2019-07-02 |
深圳宾德生物技术有限公司 |
一种靶向ox40的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
|
|
WO2019135668A1
(ko)
|
2018-01-08 |
2019-07-11 |
주식회사 프로젠 |
Ige fc 수용체의 알파 서브유닛의 세포외 도메인, 이를 포함하는 약학적 조성물 및 이의 제조방법
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
AU2019215031C1
(en)
|
2018-01-31 |
2026-02-26 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
EP3758737A4
(en)
|
2018-03-02 |
2022-10-12 |
Kodiak Sciences Inc. |
IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
|
CN110612117B
(zh)
|
2018-04-17 |
2024-04-12 |
分子模板公司 |
包含去免疫化的志贺毒素a亚基支架的her2靶向分子
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
US12144818B2
(en)
|
2018-05-30 |
2024-11-19 |
Debiopharm International, S.A. |
Method for treating cancer in a human patient by administering an anti-CD37 immunoconjugate using various dosing regimens
|
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
TWI890660B
(zh)
|
2018-06-13 |
2025-07-21 |
瑞士商諾華公司 |
Bcma 嵌合抗原受體及其用途
|
|
CN112654394B
(zh)
|
2018-06-19 |
2025-07-11 |
阿塔盖有限责任公司 |
针对补体成分5的抗体分子和其用途
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
JP2021531306A
(ja)
|
2018-07-25 |
2021-11-18 |
アドバンスド アクセラレーター アプリケーションズ エスエー |
神経内分泌腫瘍の処置の方法
|
|
US11492384B2
(en)
|
2018-09-17 |
2022-11-08 |
Gi Innovation, Inc. |
Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
|
|
US11046769B2
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
|
GB201820547D0
(en)
|
2018-12-17 |
2019-01-30 |
Oxford Univ Innovation |
Modified antibodies
|
|
EP3897648B1
(en)
|
2018-12-20 |
2023-08-23 |
Novartis AG |
Extended low dose regimens for mdm2 inhibitors
|
|
KR20210106437A
(ko)
|
2018-12-20 |
2021-08-30 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
|
|
WO2020144164A1
(en)
|
2019-01-07 |
2020-07-16 |
Bactolife Aps |
Pathogen binding proteins
|
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
CN113490528B
(zh)
|
2019-02-15 |
2024-12-03 |
诺华股份有限公司 |
3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
|
CN119039441A
(zh)
|
2019-02-21 |
2024-11-29 |
马伦戈治疗公司 |
与nkp30结合的抗体分子及其用途
|
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
|
WO2020193718A1
(en)
*
|
2019-03-27 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Recombinant proteins with cd40 activating properties
|
|
BR112021019337A2
(pt)
|
2019-03-29 |
2021-12-07 |
Atarga Llc |
Anticorpo anti-fgf23
|
|
CN120192414A
(zh)
|
2019-04-03 |
2025-06-24 |
建新公司 |
具有降低的断裂的抗αβTCR结合多肽
|
|
JP7500619B2
(ja)
|
2019-05-30 |
2024-06-17 |
アムジエン・インコーポレーテツド |
抗体の二量体化を促進するためのヒンジ領域の操作
|
|
AU2020301529B2
(en)
|
2019-06-24 |
2026-03-26 |
Universität Stuttgart |
TNFR2 agonists with improved stability
|
|
US20220363770A1
(en)
|
2019-06-28 |
2022-11-17 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
|
GB201910900D0
(en)
|
2019-07-31 |
2019-09-11 |
Scancell Ltd |
Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
|
|
US20220242962A1
(en)
|
2019-08-12 |
2022-08-04 |
Aptevo Research And Development Llc |
4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40
|
|
MX2022003507A
(es)
*
|
2019-09-25 |
2022-04-25 |
Univ Stuttgart |
Modulos de union que comprenden dominios ehd2 modificados.
|
|
CA3157509A1
(en)
|
2019-10-10 |
2021-04-15 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
BR112022007179A2
(pt)
|
2019-10-21 |
2022-08-23 |
Novartis Ag |
Inibidores de tim-3 e usos dos mesmos
|
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
|
WO2021091906A1
(en)
|
2019-11-04 |
2021-05-14 |
Amgen Inc. |
Methods for treating leukemia
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
BR112022011902A2
(pt)
|
2019-12-20 |
2022-09-06 |
Novartis Ag |
Terapias de combinação
|
|
AU2020416273A1
(en)
|
2020-01-03 |
2022-07-28 |
Marengo Therapeutics, Inc. |
Anti-TCR antibody molecules and uses thereof
|
|
WO2021146636A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
|
BR112022012310A2
(pt)
|
2020-01-17 |
2022-09-06 |
Novartis Ag |
Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
|
|
CN115397460A
(zh)
|
2020-02-27 |
2022-11-25 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
|
WO2021231376A2
(en)
|
2020-05-12 |
2021-11-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
MX2022012076A
(es)
*
|
2020-05-21 |
2022-10-13 |
Zydus Lifesciences Ltd |
Variante del fc y preparacion de la misma.
|
|
US20230257703A1
(en)
*
|
2020-06-19 |
2023-08-17 |
Iowa State University Research Foundation, Inc. |
Nanoscale polymeric micellar scaffolds for rapid and efficient antibody production
|
|
KR20230027056A
(ko)
|
2020-06-23 |
2023-02-27 |
노파르티스 아게 |
3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
|
|
TW202216761A
(zh)
|
2020-07-16 |
2022-05-01 |
瑞士商諾華公司 |
抗β細胞素抗體、其片段及多特異性結合分子
|
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
|
JP7819176B2
(ja)
|
2020-08-03 |
2026-02-24 |
ノバルティス アーゲー |
ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
|
MX2023003041A
(es)
|
2020-09-16 |
2023-05-09 |
Amgen Inc |
Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
|
|
TW202229861A
(zh)
*
|
2020-10-14 |
2022-08-01 |
中國大陸商天境生物科技（上海）有限公司 |
藉由治療性抗cd47抗體於輸血前檢驗中減輕干擾之方法
|
|
US20240002509A1
(en)
|
2020-11-06 |
2024-01-04 |
Novartis Ag |
ANTIBODY Fc VARIANTS
|
|
CA3198447A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
|
IL303328A
(en)
|
2020-12-01 |
2023-07-01 |
Aptevo Res & Development Llc |
Heterodimeric psma and cd3-binding bispecific antibodies
|
|
US20240141060A1
(en)
|
2021-01-29 |
2024-05-02 |
Novartis Ag |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
|
CN117321076A
(zh)
|
2021-02-19 |
2023-12-29 |
美国卫生及公众服务部代表 |
中和SARS-CoV-2的单结构域抗体
|
|
CN112920267B
(zh)
*
|
2021-03-09 |
2021-08-13 |
北京康乐卫士生物技术股份有限公司 |
一种抗人乳头瘤病毒31型的单克隆中和抗体及其应用
|
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
|
|
MX2023012324A
(es)
|
2021-04-20 |
2023-10-30 |
Amgen Inc |
Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes.
|
|
WO2022232376A1
(en)
|
2021-04-29 |
2022-11-03 |
Amgen Inc. |
Methods for reducing low molecular weight species of recombinantly-produced proteins
|
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
|
CN116769042A
(zh)
*
|
2021-06-17 |
2023-09-19 |
东莞市朋志生物科技有限公司 |
嵌合的免疫球蛋白
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
US12441816B2
(en)
|
2021-09-21 |
2025-10-14 |
Qilu Puget Sound Biotherapeutics Corporation |
Heterodimeric Fc for making fusion proteins and bispecific antibodies
|
|
MX2024004550A
(es)
|
2021-10-14 |
2024-04-29 |
Teneobio Inc |
Proteinas de union a la mesotelina y usos de las mismas.
|
|
US20250034559A1
(en)
|
2021-11-17 |
2025-01-30 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
|
CN115286701A
(zh)
*
|
2022-03-07 |
2022-11-04 |
江苏靶标生物医药研究所有限公司 |
一种调节哺乳动物的肠道粘膜稳态或炎症性肠病的靶点及其应用
|
|
WO2023183231A1
(en)
|
2022-03-21 |
2023-09-28 |
Amgen Inc. |
Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
|
|
CN114591988B
(zh)
*
|
2022-03-30 |
2023-01-13 |
北京贝来生物科技有限公司 |
一种激活肿瘤免疫的基因修饰干细胞制备方法
|
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
US20260035478A1
(en)
|
2022-07-27 |
2026-02-05 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
|
JP2025528068A
(ja)
|
2022-08-03 |
2025-08-26 |
ボイジャー セラピューティクス インコーポレイテッド |
血液脳関門を通過させるための組成物及び方法
|
|
WO2024049684A1
(en)
|
2022-08-30 |
2024-03-07 |
Amgen Inc. |
Live cell profiling assay
|
|
US20240076709A1
(en)
|
2022-09-06 |
2024-03-07 |
Amgen Inc. |
Lean perfusion cell culture methods
|
|
EP4598958A1
(en)
|
2022-10-05 |
2025-08-13 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
|
EP4605077A1
(en)
|
2022-10-18 |
2025-08-27 |
Confo Therapeutics N.V. |
Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
|
|
AR131758A1
(es)
|
2023-02-02 |
2025-04-30 |
Amgen Inc |
Mitigación de la fragmentación de proteínas terapéuticas durante los procesos de recolección de cultivos celulares
|
|
WO2024168061A2
(en)
|
2023-02-07 |
2024-08-15 |
Ayan Therapeutics Inc. |
Antibody molecules binding to sars-cov-2
|
|
AU2024226156A1
(en)
|
2023-02-21 |
2025-08-28 |
Teneobio, Inc. |
C-kit binding proteins, chimeric antigen receptors, and uses thereof
|
|
US20240307803A1
(en)
|
2023-03-13 |
2024-09-19 |
Amgen Inc. |
Virus filtration operations employing an oversized virus prefilter
|
|
IL322843A
(en)
|
2023-03-14 |
2025-10-01 |
Amgen Inc |
Anion exchange chromatography processes using a primary amine ligand
|
|
TW202515647A
(zh)
|
2023-06-20 |
2025-04-16 |
美商安進公司 |
用於層析和層析介質再利用之方法
|
|
TW202540169A
(zh)
|
2023-11-08 |
2025-10-16 |
法商賽諾菲公司 |
基於ｃｄ２５的溶酶體降解物及其用途
|
|
WO2025122634A1
(en)
|
2023-12-05 |
2025-06-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
|
TW202548027A
(zh)
|
2024-01-23 |
2025-12-16 |
美商安進公司 |
用於調節單株抗體電荷變體之方法
|
|
WO2025160446A1
(en)
*
|
2024-01-25 |
2025-07-31 |
Ai Proteins, Inc. |
Methods and systems for characterizing structural features of a protein
|
|
WO2025184315A1
(en)
|
2024-02-29 |
2025-09-04 |
Amgen Inc. |
Glucagon receptor agonists, conjugated to glucose-dependent insulinotropic polypeptide antibodies
|
|
WO2025193791A1
(en)
|
2024-03-14 |
2025-09-18 |
Amgen Inc. |
Intensified ultrafiltration/diafiltration processes
|
|
TW202602940A
(zh)
|
2024-04-09 |
2026-01-16 |
美商安進公司 |
激動性抗ｉｌ－２ｒｂｇ重鏈抗體
|
|
EP4635980A1
(en)
|
2024-04-19 |
2025-10-22 |
Medigene Immunotherapies GmbH |
Uni-tags specific antibody
|
|
WO2025251034A1
(en)
|
2024-05-31 |
2025-12-04 |
Amgen Inc. |
Purification method
|
|
WO2026036047A1
(en)
|
2024-08-08 |
2026-02-12 |
Altus Enterprises, Inc. |
Antibody molecules to fixa and fx and uses thereof
|
|
WO2026058155A1
(en)
|
2024-09-11 |
2026-03-19 |
Novartis Ag |
Antibodies targeting il-31
|
